CGI Pharmaceuticals, Inc.

Cellular Genomics Establishes Research Collaboration With Lilly

Cellular Genomics Establishes Research Collaboration With Lilly

December 17, 2003

BRANFORD, Conn., Dec. 17 /PRNewswire/ -- Cellular Genomics Inc. (CGI), a chemical genetics based biopharmaceutical company, today announced that it has entered into a research collaboration with Eli Lilly and Company, under which CGI will apply its chemical genetics Analog Sensitive Kinase Allele (ASKA) technology to the study of kinase drug targets selected by Lilly.

Zalicus

CombinatoRx, Incorporated Files Registration Statement for Proposed Initial Public Offering

CombinatoRx, Incorporated Files Registration Statement for Proposed Initial Public Offering

December 13, 2004

BOSTON, Dec. 13 /PRNewswire/ -- CombinatoRx, Incorporated announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All of the shares of common stock will be offered by the Company. SG Cowen & Co., LLC is acting as sole book-running manager, Pacific Growth Equities, LLC is acting as co-lead manager, and SunTrust Robinson Humphrey and A.G. Edwards are acting as co-managers for the proposed offering.

Hypnion, Inc.

Hypnion, Inc. Raises $20.1 Million in Extended Series B Financing

Hypnion, Inc. Raises $20.1 Million in Extended Series B Financing

December 19, 2005

Funds Will Advance Clinical Development of Novel Therapies for Insomnia

Epitome Biosystems

Epitome Biosystems to Develop Biomarker Assay Panels for Bristol-Myers Squibb

Epitome Biosystems to Develop Biomarker Assay Panels for Bristol-Myers Squibb

January 4, 2006

WALTHAM, Mass., Jan. 4 /PRNewswire/ -- Epitome Biosystems announced today that it has signed a technology access and product development agreement with Bristol-Myers Squibb Company (NYSE: BMY) for use of Epitome's proprietary EpiTag(TM) protein measurement platform. Epitome will develop custom antibody arrays for quantitative and high throughput measurement of proteins specified by Bristol-Myers Squibb to accelerate introduction of newly discovered biomarkers into clinical development programs.

Interactive Supercomputing Corporation

Interactive Supercomputing Secures VC Funding

Interactive Supercomputing Secures VC Funding

January 17, 2006

Funding to accelerate sales and marketing and R&D efforts

WALTHAM, Mass., Jan. 17 /PRNewswire/ -- On the heels of a successful product launch last quarter, Interactive Supercomputing, Inc. (ISC) today announced it secured a $4.5 million Series-A investment. Flagship Ventures led the round, joined by Rock Maple Ventures and CommonAngels, a network of private investors and limited partners.

IntelliVid

IntelliVid Announces $8.0 Million Series B Funding

IntelliVid Announces $8.0 Million Series B Funding

January 17, 2006

Round Led by Intel Capital, Funds Will Accelerate Company's Growth Through Expanding Sales and Marketing Efforts and Enhancing Product Line

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 17, 2006--IntelliVid Corporation, the leader in intelligent video analysis solutions for retail loss prevention, today announced it has received $8 million in Series B funding, bringing the total investment in the company to over $18 million.

VisEn Medical, Inc.

VisEn Medical Appoints Janet Lankard as Vice President of Sales and Technology Collaborations

VisEn Medical Appoints Janet Lankard as Vice President of Sales and Technology Collaborations

January 24, 2006

CAMBRIDGE, Mass., Jan. 24 /PRNewswire/ -- VisEn Medical today announced that it has appointed Janet Lankard as Vice President of Sales and Technology Collaborations. This newly created position significantly enhances VisEn's commercialization of its proprietary Fluorescence Molecular Tomography (FMT) system and optical imaging probe portfolio. In addition, Janet's efforts will also support advanced application-based partnerships with pharmaceutical and academic leaders in the field. Ms.

Zalicus

CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 Study Results in Hand Osteoarthritis

CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 Study Results in Hand Osteoarthritis

January 30, 2006

Trial Meets Primary Endpoint with Statistically Significant Reduction in Pain

IntelliVid

CVS Expands Use of IntelliVid's Intelligent Video Analysis Solution to Reduce Shrink

CVS Expands Use of IntelliVid's Intelligent Video Analysis Solution to Reduce Shrink

February 13, 2006

CAMBRIDGE -- IntelliVid Corporation, the leader in intelligent video analysis software for retail loss prevention, today announced that CVS , the country's largest drugstore chain with 5,461stores in 37 states, has expanded the use of its Video Investigator™ software in several regions.

After piloting IntelliVid's technology in one high-risk store in the Boston area, CVS has now installed Video Investigator in several stores throughout the country.

BG Medicine, Inc.

TB Alliance and BG Medicine Initiate Biomarker Discovery Program

TB Alliance and BG Medicine Initiate Biomarker Discovery Program

February 21, 2006

Project Aims to Streamline and Shorten Drug Development for Tuberculosis

New York, NY and Waltham, MA., February 21, 2006 — The Global Alliance for TB Drug Development (TB Alliance) and BG Medicine Inc. announced today a collaboration to identify biomarkers for drug efficacy in the treatment of tuberculosis (TB), a step toward faster and more efficient drug development.